VYGR - Neurocrine Sheds Its Parkinson's Gene Therapy Program While The Street Waits For Ingrezza Reacceleration
- Neurocrine has chosen to terminate development of NBIb-1817, the gene therapy for Parkinson's it acquired through its partnership with Voyager.
- Ingrezza sales have been knocked off stride by COVID-19, and it remains to be seen how quickly the company can regain the sort of growth that will excite the Street.
- The upcoming Phase II results announcement on NBI-'844 is a high-risk/high-reward opportunity in a large underserved market.
- Even with a slower Ingrezza ramp, Neurocrine shares remain undervalued and attractively priced.
For further details see:
Neurocrine Sheds Its Parkinson's Gene Therapy Program, While The Street Waits For Ingrezza Reacceleration